Key facts
- It has raised $14.5M; the latest was Early Stage VC in Aug 2025.
- Notable investors include YuanBio Venture Capital, Suzhou Angel Fund of Funds, China-Singapore Suzhou Industrial Park Development Group, Fosun Health Capital, Tenedge Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Divamics
- ·The full record, as it builds
Funding rounds
No funding rounds for Divamics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Divamics
Developer of next-generation drug discovery and development platforms aims to accelerate innovative therapies. The company's offerings feature a multi-scale molecular dynamics platform combined with proprietary algorithms, free energy methods, and advanced computational modeling and simulation services, including druggability analysis, macromolecule and small molecule screening, structural design, and optimization, helping customers benefit from precise molecular mechanism insights and novel drug design.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- divamicsbio.com/
- Ownership
- Privately Held (backing)
Divamics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Divamics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Divamics in its N-PORT filings yet. We sweep new filings monthly.